(0.56%) 5 156.71 points
(0.17%) 38 743 points
(0.61%) 16 255 points
(0.54%) $78.53
(3.92%) $2.23
(0.89%) $2 329.20
(2.97%) $27.48
(-0.24%) $963.00
(-0.09%) $0.928
(-0.40%) $10.83
(-0.19%) $0.795
(-0.10%) $91.36
Quarter results today
(bmo 2024-05-06)
Expected move: +/- 7.19%
-1.39% $ 10.64
Live Chart Being Loaded With Signals
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications...
Stats | |
---|---|
Tagesvolumen | 283.00 |
Durchschnittsvolumen | 562.00 |
Marktkapitalisierung | 12.92M |
EPS | $0 ( 2024-03-27 ) |
Last Dividend | $0.0825 ( 1999-08-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.570 |
ATR14 | $0 (0.00%) |
AETERNA ZENTARIS INC Korrelation
10 Am meisten positiv korreliert | |
---|---|
HZM.TO | 0.971 |
IGM.TO | 0.958 |
BRE.TO | 0.958 |
SOLG.TO | 0.957 |
D-UN.TO | 0.956 |
SGR-UN.TO | 0.956 |
CVD.TO | 0.954 |
AP-UN.TO | 0.95 |
TRZ.TO | 0.949 |
MPCT-UN.TO | 0.949 |
10 Am meisten negativ korreliert | |
---|---|
QBTL.TO | -0.93 |
SBB.TO | -0.919 |
SNC.TO | -0.915 |
IAF-PI.TO | -0.915 |
SFC.TO | -0.902 |
E.TO | -0.895 |
PEY.TO | -0.894 |
RQK.TO | -0.889 |
U-UN.TO | -0.878 |
VLE.TO | -0.865 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
AETERNA ZENTARIS INC Finanzdaten
Annual | 2023 |
Umsatz: | $4.50M |
Bruttogewinn: | $4.28M (95.06 %) |
EPS: | $-3.41 |
FY | 2023 |
Umsatz: | $4.50M |
Bruttogewinn: | $4.28M (95.06 %) |
EPS: | $-3.41 |
FY | 2022 |
Umsatz: | $5.64M |
Bruttogewinn: | $5.48M (97.22 %) |
EPS: | $-6.22 |
FY | 2021 |
Umsatz: | $5.26M |
Bruttogewinn: | $5.17M (98.29 %) |
EPS: | $-1.820 |
Financial Reports:
No articles found.
AETERNA ZENTARIS INC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0825 | 1999-08-11 |
Last Dividend | $0.0825 | 1999-08-11 |
Next Dividend | $0 | N/A |
Payout Date | 2007-01-02 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.0825 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SRR.V | Dividend Knight | 2023-09-28 | Bi-Monthly | 3 | 3.43% | |
HPF.TO | Dividend Knight | 2023-08-30 | Monthly | 10 | 4.45% | |
BYD.TO | Dividend Knight | 2023-09-28 | Quarterly | 22 | 0.17% | |
XCV.TO | Dividend Junior | 2023-06-26 | Quarterly | 19 | 1.84% | |
PHX.TO | Dividend King | 2023-09-28 | Quarterly | 22 | 4.31% | |
ESGE.TO | Dividend Junior | 2023-06-28 | Quarterly | 5 | 1.44% | |
ZPAY.TO | Dividend King | 2023-08-29 | Monthly | 5 | 3.46% | |
TGED.TO | Dividend Knight | 2023-08-29 | Monthly | 6 | 2.38% | |
K.TO | Dividend Knight | 2023-08-23 | Quarterly | 17 | 1.28% | |
CJR-B.TO | Dividend Knight | 2023-07-28 | Quarterly | 22 | 2.76% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -3.70 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.450 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.636 | 1.500 | -8.18 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 8.01 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.57 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 7.49 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00754 | -1.500 | 9.87 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -375.17 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -3.52 | 2.00 | -1.175 | -2.35 | [0 - 30] |
freeCashFlowPerShareTTM | -3.53 | 2.00 | -1.764 | -3.53 | [0 - 20] |
debtEquityRatioTTM | 0.0153 | -1.500 | 9.94 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.951 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -4.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -61.35 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.122 | 0.800 | -2.52 | -2.02 | [0.5 - 2] |
Total Score | -1.290 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.30 | 1.000 | -0.333 | 0 | [1 - 100] |
returnOnEquityTTM | -0.636 | 2.50 | -5.26 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -3.53 | 2.00 | -1.176 | -3.53 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -3.52 | 2.00 | -1.175 | -2.35 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.166 | 1.500 | -2.23 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.81 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.84 |
AETERNA ZENTARIS INC
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.